Director Mark Coleman's Stock Transactions in Axsome Therapeutics

Axsome Therapeutics, Inc. director Mark Coleman filed a Form 4 disclosing several stock transactions. On June 8, 2026, Coleman received 1,429 shares through the settlement of restricted stock units that were granted on June 6, 2025 and vested on their one-year anniversary. This transaction increased his direct holdings to 31,032 shares. Two days later on June 10, 2026, Coleman sold 643 shares at a weighted average price of $249 per share through a pre-approved 10b5-1 trading plan, reducing his direct holdings to 30,389 shares. The sale was conducted to cover taxes associated with the RSU settlement. Additionally, Coleman holds 403,856 shares indirectly through an entity where he maintains voting and dispositive power. The filing was signed by attorney-in-fact Nick Pizzie on June 10, 2026.